Merus Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Merus de 19.1% y 44.1% por año respectivamente. Se prevé que el BPA crezca en un 26.5% al año. Se espera que la rentabilidad financiera sea de -49.2% en 3 años.

Información clave

18.6%

Tasa de crecimiento de los beneficios

25.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.1%
Tasa de crecimiento de los ingresos	45.0%
Rentabilidad financiera futura	-49.2%
Cobertura de analistas	Good
Última actualización	25 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02

Merus posts positive efficacy data from early-stage zenocutuzumab cancer study

Jun 04

Merus EPS misses by $0.10, misses on revenue

May 06

Is Merus N.V. (NASDAQ:MRUS) Popular Amongst Institutions?

Mar 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:MRUS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	80	-227	-177	-191	10
12/31/2025	55	-222	-190	-171	13
12/31/2024	38	-191	-172	-161	13
12/31/2023	44	-155	-146	-142	N/A
9/30/2023	46	-177	-142	-136	N/A
6/30/2023	41	-178	-159	-150	N/A
3/31/2023	43	-152	-151	-140	N/A
12/31/2022	42	-131	-158	-150	N/A
9/30/2022	46	-64	-157	-151	N/A
6/30/2022	53	-54	-137	-133	N/A
3/31/2022	52	-76	-126	-125	N/A
12/31/2021	49	-67	-60	-60	N/A
9/30/2021	43	-80	-53	-52	N/A
6/30/2021	38	-89	-42	-41	N/A
3/31/2021	32	-79	-37	-35	N/A
12/31/2020	30	-86	-81	-80	N/A
9/30/2020	29	-83	-76	-75	N/A
6/30/2020	28	-69	-80	-78	N/A
3/31/2020	29	-65	-77	-75	N/A
12/31/2019	31	-55	-66	-63	N/A
9/30/2019	37	-32	-61	-56	N/A
6/30/2019	35	-34	-63	-58	N/A
3/31/2019	36	-26	-50	-45	N/A
12/31/2018	38	-28	-50	-46	N/A
9/30/2018	34	-41	-48	-46	N/A
6/30/2018	33	-45	-44	-43	N/A
3/31/2018	34	-66	-55	-54	N/A
12/31/2017	26	-78	-46	-45	N/A
9/30/2017	18	-100	N/A	-44	N/A
6/30/2017	12	-87	N/A	-33	N/A
3/31/2017	6	-66	N/A	-27	N/A
12/31/2016	3	-50	N/A	-27	N/A
9/30/2016	4	-25	N/A	-27	N/A
6/30/2016	3	-26	N/A	-30	N/A
3/31/2016	3	-27	N/A	-29	N/A
12/31/2015	2	-25	N/A	-25	N/A
9/30/2015	2	-25	N/A	-23	N/A
6/30/2015	2	-23	N/A	-19	N/A
3/31/2015	1	-20	N/A	-17	N/A
12/31/2014	2	-21	N/A	-18	N/A
12/31/2013	1	-14	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MRUS siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que MRUS siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que MRUS siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (44.1% al año) de MRUS crezcan más rápidamente que los del mercado US (8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (44.1% al año) de MRUS crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: MRUS se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Merus Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.6% to US$59.18

Price target increased by 16% to US$51.60

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$3.63 loss

Price target increased by 8.6% to US$40.67

Recent updates

Merus N.V., Annual General Meeting, May 07, 2024

Price target increased by 7.6% to US$59.18

Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Price target increased by 16% to US$51.60

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

EVP, Company Secretary notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

New major risk - Revenue and earnings growth

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Merus Appoints Greg Perry as Chief Financial Officer

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$3.63 loss

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Price target increased by 8.6% to US$40.67

Price target increased by 8.5% to US$39.67

Chief Business Officer exercised options to buy US$1.9m worth of stock.

Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021)

Now 21% undervalued

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus N.V. Announces Executive Changes

Price target decreased to US$37.11

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$38.44

Merus N.V. Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Merus N.V. Presents Clinical Data on Zenocutuzumab in NRG1-Fusion Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates increase by 15%

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus N.V., Annual General Meeting, May 31, 2022

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Executive VP exercised options and sold US$947k worth of stock

Merus N.V. Announces Publication of Abstract on MCLA-129 At the American Association for Cancer Research 2022 Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Consensus revenue estimates increase by 17%

Merus N.V. Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at San Antonio Breast Cancer Symposium

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Price target increased to US$41.29

Third quarter 2021 earnings released: US$0.39 loss per share (vs US$0.79 loss in 3Q 2020)

Price target increased to US$33.50

CTO & Senior VP exercised options and sold US$54k worth of stock

Second quarter 2021 earnings released: US$0.71 loss per share (vs US$0.62 loss in 2Q 2020)

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Consensus forecasts updated

CEO, President exercised options to buy US$298k worth of stock.

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Forecast to breakeven in 2024